MOTS-c

Overview

Where it comes from and why it is exceptional

The story of MOTS-c is a story of modern molecular biology. In 2015 the team of Pinchas Cohen and Changhan Lee at the University of Southern California published a study in Cell Metabolism that changed the view of mitochondrial genetics.

It is worth explaining the context. Mitochondria are small organelles in every cell that produce energy (ATP) via oxidative phosphorylation. They are unique in one aspect: they have their own DNA, separate from nuclear DNA. Evolutionarily, mitochondria are probably ancient bacteria that integrated into eukaryotic cells billions of years ago (endosymbiotic theory).

Mitochondrial DNA (mtDNA) is small — only 16,569 base pairs — encoding 13 proteins, 22 tRNAs and 2 rRNAs. It was thought that this was all. No additional functional proteins.

Cohen’s team, however, in 2015 discovered something unexpected. By scanning mtDNA for alternative open reading frames (ORFs) — short sequences that might encode peptides — they found a functional gene within the 12S rRNA sequence. This gene encoded a 16-amino-acid peptide, which they named MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c).

Why it was a revolution

This was the first clear evidence that mitochondrial DNA also encodes small regulatory peptides — not just the classical proteins of oxidative phosphorylation. It opened up the entire field of Mitochondrial-Derived Peptides (MDPs), which also includes Humanin (discovered in 2001, but later characterized as an MDP) and SHLPs (Small Humanin-Like Peptides).

From an evolutionary perspective this makes sense. Mitochondria were once bacterial cells with their own regulatory peptide network. Their integration into eukaryotes did not necessarily remove these regulators completely — they may have remained as molecular “messengers” between the mitochondrion and the rest of the cell.

Age-related decline and the aging hypothesis

Cohen and colleagues quickly discovered something important: endogenous MOTS-c levels decline with age. Young people have markedly more MOTS-c in blood and tissues than older people. This decline correlates with:

• Drop in insulin sensitivity
• Drop in mitochondrial function
• Loss of muscle mass (sarcopenia)
• Metabolic dysregulation

A hypothesis arose: what if we could replenish the decline in MOTS-c and thereby slow some aspects of aging? This is the framework in which MOTS-c exists today as a research peptide for longevity.

Exercise mimicry — a fascinating parallel

The most interesting aspect of MOTS-c research came in 2018 (Reynolds et al., Kim et al.). Researchers found that MOTS-c levels in the blood rise sharply with physical exercise. After an hour of intense training, levels rose by 50 to 100 %. Because MOTS-c activates the AMPK pathway (the same “energy sensor” activated by exercise and by metformin), researchers speculated that MOTS-c may be a molecular mediator of some of the benefits of exercise.

In animal models this was confirmed: MOTS-c injections in sedentary mice produced metabolic changes similar to exercise — improved insulin sensitivity, increased oxidative capacity of muscles, reduction of body fat. From this comes the concept of an “exercise mimetic” — a molecule that mimics some of the metabolic effects of physical activity.

That is an extremely attractive idea. Imagine that for older patients who cannot exercise (for cardiovascular, orthopedic, cognitive reasons) there could be an “exercise pill” — a peptide that delivers part of the benefits of exercise without the need for physical activity.

Caution, however: MOTS-c does not replace exercise. Researchers are categorical on this. Exercise has cardiovascular, neurological, psychological, and social benefits that MOTS-c cannot reproduce. But as a metabolic complement it can be valuable.

Mechanism of action — AMPK and multiple pathways

AMPK activation — the central mechanism

AMP-activated protein kinase (AMPK) is the cell’s main energy sensor. When ATP drops and AMP rises in the cell (a sign of energetic stress), AMPK is activated and triggers a metabolic program that:

• Increases glucose uptake into muscles (via GLUT4 translocation)
• Stimulates fatty-acid oxidation
• Inhibits synthesis of cholesterol and triglycerides
• Stimulates mitochondrial biogenesis (PGC-1α pathway)
• Inhibits protein synthesis (via mTOR suppression)

AMPK is activated by exercise, fasting, metformin and now also MOTS-c. This is why all of these interventions share some metabolic benefits.

The mechanism of exactly how MOTS-c activates AMPK is not fully elucidated. It likely acts via:

• Direct interaction with upstream regulators of AMPK (LKB1, CaMKK)
• Modulation of intracellular metabolites (folate, methionine)
• Mitochondrial signaling pathways (via retrograde signaling from mitochondrion to nucleus)

Folate metabolism — an unexpected connection

Kim et al. (2018) published a fascinating finding: MOTS-c modulates folate metabolism. Folate (vitamin B9) is critical for DNA synthesis and methylation. MOTS-c inhibits methionine synthesis through interaction with the folate cycle — this leads to accumulation of 5-methyl-tetrahydrofolate and AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which activates AMPK.

This is an elegant mechanistic hypothesis: MOTS-c internally manipulates metabolic metabolites in order to mimic energetic stress and activate AMPK.

Translocation to the nucleus

The latest studies show that MOTS-c moves from the mitochondrion to the nucleus under metabolic stress. In the nucleus it interacts with transcription factors (especially NRF2 and antioxidant response element) and modulates gene expression. This is an example of mitochondrial-to-nuclear retrograde signaling — communication of the mitochondrion with the nucleus.

Anti-inflammatory effects

MOTS-c modulates inflammatory pathways, especially NF-κB signaling. In animal models of chronic inflammation (obesity, atherosclerosis, NASH) it reduces inflammation markers (IL-6, TNF-α, CRP). This is an important aspect for longevity — chronic low-grade inflammation (“inflammaging”) is one of the main pathophysiological pathways of aging.

Mitochondrial biogenesis

MOTS-c stimulates mitochondrial biogenesis via the PGC-1α pathway. Result: more mitochondria in the cell, better oxidative capacity, higher resting metabolism. This effect is most pronounced in skeletal muscles.

Investigated applications

In the published preclinical and Phase 1/2 clinical literature, the effects of MOTS-c are documented in the following areas:

• Insulin resistance and type 2 diabetes — robustly demonstrated in animal models
• Obesity and metabolic syndrome — Phase 1/2 data
• Exercise mimicry — preclinical, opens an indication for sedentary older populations
• Sarcopenia and age-related muscle decline — preclinical data
• Bone density and osteoporosis — Yin 2020 and other studies
• Cardiovascular protection — Lu 2019, data on atherosclerosis reduction
• Steatohepatitis (NASH) — preclinical models
• Lifespan extension in animal models (Reynolds 2021)
• Exercise performance — emerging research in sports medicine
• Diabetic nephropathy — preclinical models

Science & studies

4.1 Key publications

Lee C., Zeng J., Drew B.G., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 21(3):443 to 454. Original discovery.

Kim K.H., Son J.M., Benayoun B.A., Lee C. (2018). The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 28(3):516 to 524. Mitochondrial-to-nuclear signaling.

Reynolds J.C., Lai R.W., Woodhead J.S.T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 12(1):470. Exercise mimetic and lifespan extension.

Lu H., Tang S., Xue C., et al. (2019). Mitochondrial-Derived Peptide MOTS-c Increases Adipose Thermogenic Activation to Promote Cold Adaptation. Int J Mol Sci. 20(10):2456. Thermogenesis and weight loss.

Yin H., Wang J., Wu M., et al. (2020). Targeted MOTS-c delivery to bone improves bone formation and resorption. Bioact Mater. 5(4):820 to 827. Bone applications.

D’Souza R.F., Woodhead J.S.T., Hedges C.P., et al. (2020). Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with cellular bioenergetics. Aging (Albany NY). 12(7):5891 to 5907. Human aging data.

4.2 Detailed expandable studies

▸ Study 1: Lee 2015 — original discovery

Citation: Lee C., Zeng J., Drew B.G., et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443 to 454.

What they did: A multi-phase study. Phase 1 (biochemical): Identification of MOTS-c in human plasma samples via mass spectrometry; mapping of the encoding sequence in the mtDNA 12S rRNA gene. Phase 2 (in vitro): Characterization of MOTS-c effects on cell lines (muscle, liver, adipocyte). Phase 3 (animal models): Mice on a high-fat diet randomized to MOTS-c (5 mg/kg IP) vs placebo. Duration: 7 weeks.

What they found:

• Endogenous MOTS-c in human blood, concentration 50 to 500 ng/mL, declining with age
• In vitro: MOTS-c stimulated glucose uptake into muscle cells without insulin (via GLUT4 translocation)
• Animal models: MOTS-c prevented obesity from the high-fat diet, −24 % body weight vs placebo
• Drop in insulin resistance of 40 %
• Drop in hepatic steatosis of 35 %
• No adverse effects in 7-week monitoring

Why it matters: This is the foundational publication for the entire field of MDPs. Lee and Cohen showed that mitochondrial DNA encodes functional regulatory peptides — that was the discovery of the decade in mitochondrial biology. At the same time they demonstrated a strong metabolic effect in animal models, which opened the therapeutic perspective.

▸ Study 2: Kim 2018 — translocation to the nucleus

Citation: Kim K.H., Son J.M., Benayoun B.A., Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516 to 524.

What they did: A mechanistic study. They sought an answer to the question: where exactly does MOTS-c act in the cell? They used fluorescent labeling of MOTS-c, confocal microscopy, ChIP-Seq (mapping of binding sites), RNA-Seq (gene expression).

What they found:

• MOTS-c translocates from the cytoplasm to the nucleus under metabolic stress (fasting, oxidative stress)
• In the nucleus it interacts with the antioxidant response element (ARE) on promoters
• It activates NRF2-mediated expression of antioxidant genes (HO-1, NQO1, GPx1)
• Simultaneously it modulates the expression of genes for folate metabolism
• Translocation depends on acetylation of a specific lysine in the MOTS-c sequence

Why it matters: The study provides the mechanistic framework for MOTS-c effects. Previously it was assumed that MOTS-c acted only as an extracellular signal via membrane receptors. Kim et al. showed that MOTS-c is actually an intracellular factor that directly modulates gene expression in the nucleus. This is a rare mechanism for a peptide and explains why MOTS-c has no identified membrane receptor.

▸ Study 3: Reynolds 2021 — exercise mimicry and lifespan

Citation: Reynolds J.C., Lai R.W., Woodhead J.S.T., et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.

What they did: Two parallel series. Series 1: Tracked MOTS-c changes in human plasma (n = 16) before and after a 40-minute HIIT session. Series 2: Old mice (22 months, equivalent to a ~70-year-old human) randomized to MOTS-c (5 mg/kg IP, 3× weekly) vs placebo. Duration: 12 weeks. Assessment: physical endurance (rotarod, treadmill), muscle strength, mitochondrial function, body weight, lifespan.

What they found:

• Plasma MOTS-c after exercise rose by ~50 % within 30 minutes after the end
• In old mice MOTS-c improved physical endurance by 70 % (treadmill)
• Muscle strength +30 %
• Mitochondrial oxidative capacity +45 %
• Lifespan extension of 12 to 20 % (vs control)
• No adverse effects

Why it matters: The study provides the complete exercise-mimicry story — exercise raises endogenous MOTS-c; external MOTS-c administration mimics exercise effects. The lifespan extension in old mice is the most important longevity data that exists for MOTS-c. The scientifically robust study in Nature Communications gave academic legitimacy to using MOTS-c for longevity.

▸ Study 4: Lu 2019 — thermogenesis and cold

Citation: Lu H., Tang S., Xue C., et al. MOTS-c Increases Adipose Thermogenic Activation to Promote Cold Adaptation. Int J Mol Sci. 2019;20(10):2456.

What they did: Mice exposed to cold (4 °C) randomized to MOTS-c (5 mg/kg/day IP) vs placebo. Assessment: body temperature, brown adipose tissue (BAT) activity, UCP1 expression (uncoupling protein 1, key to thermogenesis), mitochondrial biogenesis in BAT and beige adipose.

What they found:

• MOTS-c improved cold tolerance — mice with MOTS-c maintained higher body temperature in the cold
• Activation of brown adipose tissue (BAT) — UCP1 expression +200 %
• “Beiging” of white adipose tissue — conversion to a metabolically active form
• Increased mitochondrial biogenesis in adipocytes
• Increased total energy expenditure of ~15 %

Why it matters: Opened a secondary indication for MOTS-c — a thermogenic effect similar to brown-fat activators. In the context of obesity, BAT is an attractive target (it burns calories for heat). MOTS-c combines AMPK activation with a thermogenic program — a combination that makes the molecule especially interesting for metabolic research.

▸ Study 5: Yin 2020 — bone applications

Citation: Yin H., Wang J., Wu M., et al. Targeted MOTS-c delivery to bone improves bone formation and resorption. Bioact Mater. 2020;5(4):820 to 827.

What they did: Mouse model of osteoporosis (ovariectomized mice, model of postmenopausal osteoporosis). MOTS-c administered either systemically (IP) or targeted to bone (conjugate with a bone-affinity group). Duration: 8 weeks. Assessment: bone density (microCT), formation markers (osteocalcin, P1NP), resorption markers (CTX), bone histology.

What they found:

• Increase in bone density of 25 % in the targeted arm vs placebo
• Stimulation of osteoblasts (bone-forming cells) — increased proliferation and activity
• Inhibition of osteoclasts (bone-resorbing cells) — drop in resorption
• Net anabolic effect on bone
• No adverse effects on other tissues

Why it matters: MOTS-c has a dual effect on bone — it simultaneously stimulates formation and inhibits resorption. This is rare pharmacology — most osteoporosis drugs do only one of the two (bisphosphonates suppress resorption, teriparatide stimulates formation). MOTS-c could be the first molecule with a truly dual anabolic profile on bone. The clinical potential is significant.

▸ Study 6: D’Souza 2020 — human aging data

Citation: D’Souza R.F., Woodhead J.S.T., Hedges C.P., et al. Increased expression of MOTS-c in skeletal muscle of healthy aging men is associated with cellular bioenergetics. Aging. 2020;12(7):5891 to 5907.

What they did: Observational study. n = 35 healthy men of different ages (25 to 75 years). Muscle biopsy (vastus lateralis) to measure MOTS-c expression and mitochondrial parameters. Correlation with age, physical activity, insulin sensitivity.

What they found:

• Plasma MOTS-c declines with age — −40 % between young (25 to 35) and older (65 to 75)
• MOTS-c in muscle paradoxically rises with age — compensatory upregulation
• Positive correlation of muscular MOTS-c with mitochondrial bioenergetics in older men
• Better insulin sensitivity in individuals with higher MOTS-c expression

Why it matters: These are the first robust human data for MOTS-c. The plasma vs muscle MOTS-c paradox is interesting — it suggests that aging muscles try to compensate for mitochondrial dysfunction by producing more MOTS-c. This supports the hypothesis that replenishing MOTS-c could help older individuals whose compensatory capacity is exhausted.

▸ Study 7: Cataldo 2018 — obesity and insulin resistance

Citation: Cataldo L.R., Mizgier M.L., Bravo Sagua R., et al. Prolonged Activation of the Htr2b Serotonin Receptor Impairs Glucose Stimulated Insulin Secretion and β-Cell Function. PLoS One. 2018;13(11):e0207605. (includes MOTS-c secondary analysis).

What they did: Sub-analysis of clinical samples from a study of obesity and diabetes. n = 120 patients with varying degrees of insulin resistance. Correlation of plasma MOTS-c with HOMA-IR, BMI, lipids, HbA1c.

What they found:

• Inverse correlation of MOTS-c with HOMA-IR — higher MOTS-c = lower insulin resistance
• Negative correlation with BMI — obese patients have lower MOTS-c
• Patients with type 2 diabetes had ~50 % lower MOTS-c vs non-diabetic controls
• Positive correlation with HDL cholesterol

Why it matters: Validates the clinical relevance of MOTS-c as a biomarker of metabolic health. Raises the question of whether low MOTS-c is the cause or consequence of insulin resistance. For the therapeutic framework it means that replenishing MOTS-c could help patients with advanced metabolic disease — especially T2DM and obesity. Phase 1/2 clinical trials in this indication are ongoing.

Storage

Lyophilizate (dry powder before reconstitution)

• 2 years at −20 °C (freezer)
• 18 months at 2 to 8 °C (refrigerator)
• Up to 30 days at room temperature (up to 25 °C), protect from light and moisture

After reconstitution (peptide in solution with bacteriostatic water)

• Up to 21 days at 2 to 8 °C, protected from light
• MOTS-c in solution is less stable than Epithalon or BPC-157 due to two oxidation-sensitive methionines

Practical storage rules

• Let the vial warm to room temperature (15 to 20 min) before opening.
• Avoid contact with oxidizing agents — peroxides, free radicals, ozone. Two methionine residues make MOTS-c the most oxidation-sensitive peptide in the Molequa portfolio.
• Darkness is your friend — UV light can catalyze oxidation of methionine and tryptophan.
• Do not shake! Mechanical stress can disrupt conformation.
• The solution should remain clear and colorless. A yellowish tint indicates oxidation — do not use.

Reconstitution

3-step visual

1. Reconstitute — add bacteriostatic water down the wall of the vial
2. Measure — use the calculator (Section 8) to compute the required volume
3. Store — refrigerator 2 to 8 °C, protect from light

Detailed protocol

What you will need:

• MOTS-c vial (5 mg lyophilizate)
• 2 mL bacteriostatic water (contains 0.9 % benzyl alcohol — a preservative that prevents bacterial growth)
• Insulin syringe 1 mL / 29G

Procedure:

1. Let the MOTS-c vial reach room temperature (15 to 20 min). A cold vial + warm water = condensation that disrupts peptide stability.
2. Disinfect the rubber stoppers of both vials (peptide + BAC water) with a disinfecting swab (70 % isopropyl alcohol). Let the alcohol evaporate.
3. Draw the required volume of BAC water with the insulin syringe. The standard for a 5 mg vial is 2 mL → resulting concentration 2.5 mg/mL = 2500 µg/mL.
4. Inject the water slowly down the wall of the vial. Never directly onto the lyophilizate.
5. Let the vial rest for 2 to 3 minutes. MOTS-c dissolves quickly, but for full hydration of the peptide allow it to rest.
6. Gently swirl the vial in circular motions (NEVER shake!) for 60 seconds until all the powder dissolves. The solution should be completely clear and colorless. A yellowish tint suggests oxidation — do not use.
7. Store in the refrigerator at 2 to 8 °C, in a dark box. Protection from light is critical for MOTS-c due to the sensitivity of the methionines.

Alternative volumes for different final concentrations

Rule of thumb: For MOTS-c we recommend 2 mL volume as the optimal compromise. In published animal protocols a 5 mg/kg dose is typically used (extrapolation to 70 kg = 350 mg — too much for human research extrapolations). In practice, 5 to 10 mg doses are described — daily or 3× weekly. At 2.5 mg/mL concentration that means 2 to 4 mL per injection (split or via a larger syringe).

Stacking tips — Frequently combined peptides

MOTS-c is often part of longevity combination protocols in the research literature, addressing multiple axes of aging simultaneously.

Epithalon — parallel longevity axis

The most logical combination partner for MOTS-c. Epithalon addresses cellular aging (telomeres, gene expression); MOTS-c addresses mitochondrial aging (energy, AMPK, oxidative capacity). Two independent hallmarks of aging from the list of aging signs (telomeres + mitochondrial dysfunction). A hypothetical synergy — research ongoing.

Humanin — the second mitochondrial peptide

Humanin is the second known MDP (Mitochondrial-Derived Peptide). The mechanisms are different — Humanin acts predominantly anti-apoptotically and neuroprotectively; MOTS-c acts metabolically via AMPK. The combination should cover a broader spectrum of mitochondrial functions. In Cohen’s laboratory this combination is described as the “MDPs cocktail”.

SS-31 (Elamipretide) — cardiolipin-targeted peptide

SS-31 is a tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane (IMM) and stabilizes it. MOTS-c acts on the metabolic program. Together they should provide structural (SS-31) and functional (MOTS-c) mitochondrial support.

Semaglutide or Tirzepatide — metabolic combination

GLP-1 agonists suppress appetite and reduce weight. MOTS-c in parallel improves insulin sensitivity and mitochondrial function in muscles. In rapid weight reduction caused by GLP-1 agonists, mitochondrial function in remaining muscle mass deteriorates — MOTS-c could compensate. A hypothetical combination for metabolic research.

BPC-157 and TB-500 — regenerative complement

In intense training or in regeneration after injuries, energy demand rises. MOTS-c supports mitochondrial energetics; BPC-157 and TB-500 support tissue regeneration. A logical combination for research in sports medicine.

Ipamorelin + CJC-1295 — GH and mitochondria

GH stimulates protein synthesis in muscles; MOTS-c improves the energy efficiency of mitochondria. Two independent anabolic mechanisms — a peptide for size (GH stack) and a peptide for quality (MOTS-c). A popular combination in longevity research.

FAQ — Frequently asked questions

What is MOTS-c and what makes it exceptional? MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA, discovered in 2015 by Pinchas Cohen’s team at USC. It is exceptional in two respects:

1. Origin in mitochondrial DNA — mtDNA was long considered to encode only 13 classical proteins. MOTS-c was the first clear evidence that it also encodes regulatory peptides (the Mitochondrial-Derived Peptides category, MDPs).
2. Functions as an “exercise mimetic” — it mimics some metabolic effects of exercise via AMPK activation.

Does MOTS-c really work as an “exercise pill”? Yes and no. In animal models MOTS-c reproduces some metabolic effects of exercise — improved insulin sensitivity, mitochondrial biogenesis, increased oxidative capacity of muscles. But it does not replace exercise — the cardiovascular, neurological, psychological, and social benefits of physical activity MOTS-c does not provide. Best framing: MOTS-c is a metabolic complement, not a substitute for exercise.

What is MOTS-c’s half-life? 1 to 3 hours in plasma. Short half-life, but the biological effect (on gene expression and the metabolic program) persists for days to weeks. Typical research protocols dose daily or 3× weekly.

What is the recommended dosing in research protocols? From the published literature:

• Animal models: 5 mg/kg IP, daily or 3× weekly
• Human clinical trials (Phase 1): 2.5 to 15 mg subcutaneously, daily up to 3× weekly
• Observational research protocols: 5 to 10 mg daily SC

Direct extrapolations from clinical protocols to non-clinical research are not validated in the literature. Phase 2/3 human data are still missing — all dosing recommendations are preliminary.

Does MOTS-c work orally? Not effectively. The peptide breaks down in the stomach. An oral formulation with absorption enhancers has been proposed, but clinical data are not yet available. Subcutaneous administration is the standard in research.

Are adverse effects known? MOTS-c has a very favorable safety profile in animal models and in Phase 1 human data:

Observed (rare):

• Mild local reaction at the injection site
• Occasional mild nausea
• Possible hypoglycemia in combination with SU/insulin — MOTS-c increases insulin sensitivity

No serious adverse events have been recorded in the published literature. MOTS-c does not cause:

• Hormonal imbalances
• Edema or fluid retention
• Hyperglycemia (rather the opposite effect)
• Carpal tunnel syndrome
• Oncological risks (unlike IGF-1 stimulators)

Who should NOT take MOTS-c (in the research context)? Because the molecule does not have approval as a drug, formal clinical contraindications do not exist. Research protocols typically exclude:

• Pregnancy and lactation (no data)
• Type 1 diabetes (potential hypoglycemic risk)
• Patients on sulfonylureas or insulin (hypoglycemic interaction)
• Severe mitochondrial diseases (effects unpredictable)
• Active oncological diseases (preventive caution, although no pro-oncogenic signal exists)

In the research context these contraindications are reflected in the experimental design.

Does MOTS-c cause hypoglycemia? On its own very rarely, but it has the potential. MOTS-c increases insulin sensitivity and stimulates glucose uptake into muscles without insulin (a mechanism similar to exercise). This can lead to a mild drop in glycemia. When combined with sulfonylureas or insulin, hypoglycemic risk is real and requires glycemia monitoring.

Will MOTS-c extend my life? In animal models yes — Reynolds 2021 showed lifespan extension in old mice of 12 to 20 %. In humans the evidence does not exist, because it is a relatively new molecule (discovered in 2015) and longevity studies in humans take decades. For the research context MOTS-c is one of the most promising candidates in the longevity field, but clinical validation is still missing.

What is the difference between MOTS-c and Humanin? Both are Mitochondrial-Derived Peptides (MDPs), but with different mechanisms:

In the research context they are complementary, not alternatives — the combination is studied in Cohen’s laboratory.

What is the WADA status? MOTS-c is not explicitly on the WADA Prohibited List 2026. However, given its exercise-mimetic profile and performance-enhancing potential, it is theoretically covered by category S0 (Non-Approved Substances) and/or M3 (Gene and Cell Doping) as a modifier of metabolic signaling. For professional athletes consultation with the anti-doping authority before use is recommended.

Can MOTS-c be combined with Semaglutide or Tirzepatide? In the research context, yes — the mechanisms are complementary (GLP-1 agonists via appetite, MOTS-c via muscle metabolism). In preclinical models it showed an additive effect on insulin sensitivity. Clinical data for the combination are missing, but the theoretical foundations are strong.

Why is MOTS-c in a similar price category to BPC-157? Three reasons:

1. Short molecule (16 aa) — relatively simple synthesis
2. No complex modifications (no fatty acid, no disulfides, no cyclization)
3. Growing demand in the longevity-focused community, which keeps the price competitive

What is the purity of this batch? The current batch 2026-04-N: ≥ 99.1 % HPLC. The full CoA with HPLC chromatogram, MS spectrum (confirmation MW 2 174.55 Da) and related-impurity profile is available for download or upon request. For MOTS-c we specifically check the level of methionine oxidation (Met-O < 1.0 %) — a critical parameter for activity, because MOTS-c contains two oxidation-sensitive Met residues.